The release from prison of reality TV stars Todd and Julie Chrisley Wednesday is the latest in a flurry of pardons that President Donald Trump has handed out in recent weeks -- including some to ...

A light flurry of snow chilled the crowd as author Terry Tempest Williams, Utah Senate Minority Leader Luz Escamilla, Regina Lopez-Whiteskunk of the Ute Mountain Ute Tribe and Latiné university ...

Inspired by Westwood's classics, Tempest Rising feels like the closest we have to a new Command and Conquer. But balancing between its two factions, the GDF and the Dynasty, has so far been a ...

Accompanying the Tempest and Gemini into the world is a series of new fittings for the rest of the range, including various packs aptly called Beach Days, Road Trips, and Snow Days, but also new ...

Tempest Rising is happy to play it safe. That's fine, sometimes. Games don't have to constantly innovate or be daring to make themselves interesting. However, Tempest Rising takes so few risks and ...

The problem with Tempest Rising's multiplayer is that while it's perfectly competent at recreating a slice of the old Command & Conquer multiplayer with a pair of new and interesting factions, it ...

Tempest has a phase 3-ready PPARα antagonist, amezalpat, that it wants to study as a first-line treatment for hepatocellular carcinoma, the most common type of primary liver cancer. The biotech ...

Tempest Rising, a real-time strategy game that's being called a "spiritual successor" and an homage to Command & Conquer, is now available to everyone.

Though on the surface it’s a simple tribute to Command and Conquer, Tempest Rising breaks free of its influences with a visual style and mechanical flourishes all of its own. Its core ideas may ...

Tempest Rising’s two good-sized single-player campaigns are a large helping of comfort food for RTS fans old enough to remember Command & Conquer in its heyday, and a way for everyone else to ...

Tempest Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $50.18. The stock’s fifty day moving average is $10.23 and its two-hundred day moving average is $11.90.

Tempest to lead Phase 3 liver cancer trial with free atezolizumab supply from Roche. Scotia Capital downgrades Tempest stock from Sector Outperform to Sector Perform. Market-moving news hits ...